

# Coromandel International

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	CRIN IN
Equity Shares (m)	295
M.Cap.(INRb)/(USD b)	626.6 / 7.1
52-Week Range (INR)	2720 / 1588
1, 6, 12 Rel. Per (%)	-10/-10/21
12M Avg Val (INR M)	1335

## Financials & Valuations (INR b)

Y/E Mar	2026E	2027E	2028E
Sales	312.8	348.7	374.3
EBITDA	33.6	41.6	45.8
PAT	23.1	29.7	33.6
EBITDA (%)	10.7	11.9	12.2
EPS (INR)	78.6	100.8	114.0
EPS Gr. (%)	28.3	28.2	13.2
BV/Sh. (INR)	441.2	528.0	628.0

## Ratios

Net D/E	-0.2	-0.4	-0.4
RoE (%)	19.2	20.8	19.7
RoCE (%)	20.5	21.7	20.6
Payout (%)	17.8	13.9	12.3

## Valuations

P/E (x)	27.0	21.1	18.6
EV/EBITDA (x)	17.9	13.8	11.9
Div Yield (%)	0.7	0.7	0.7
FCF Yield (%)	-1.0	4.8	4.1

## Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	56.9	56.9	57.2
DII	15.9	15.9	21.3
FII	14.6	14.4	7.8
Others	12.7	12.9	13.8

**CMP: INR2,125      TP: INR2,800 (+32%)      Buy**

## Favorable agri outlook to support growth momentum

### Operating performance in line

- Coromandel International (CRIN) continued to deliver healthy operating performance in 2QFY26 (EBIT up 15% YoY), supported by continued traction in crop protection (EBIT up 34% YoY) and nutrients and allied (EBIT up 16% YoY).
- A favorable agricultural scenario, supported by above-normal monsoon and high reservoir levels, is expected to sustain the growth trajectory. Moreover, the rising demand for crop protection products, easing global agrochemical channel inventories, the integration of NACL Industries (a company primarily engaged in the agrochemical sector and specializing in crop protection products like insecticides, fungicides, and herbicides), capacity expansion, introduction of new molecules in the crop protection segment, and the rising consumption of NPK are expected to reinforce growth going forward.
- We have modeled the acquisition of NACL Industries completed during the quarter and raised our revenue estimates by 5%/7%/8% and earnings estimates by 4% for FY26/FY27/FY28, respectively. We value the company at ~28x FY27E EPS to arrive at a **TP of INR2,800. Reiterate BUY**

### Healthy performance across segments drives profitability

- CRIN reported revenue of INR96.5b (est. INR85.8b) in 2QFY26, up 30% YoY. Total manufacturing fertilizer volumes (NPK+DAP) declined marginally by 1% YoY to ~1.1mmt, and total phosphate fertilizer manufacturing volumes (including SSP) declined 2% YoY to 1.29mmt. Overall phosphatic volumes (NPK + DAP) increased 7% to 1.4mmt.
- Nutrient & other allied business revenue rose 28% YoY to INR86.6b, while crop protection business revenue grew 42% YoY to INR10.7b. Standalone Crop protection (i.e. ex NACL) business grew 10% to INR8.3b.
- EBITDA grew 18% YoY to INR11.5b (est. in-line). According to our calculations, manufacturing EBITDA/mt (including SSP) stood at INR6,340 (up 17% YoY), while EBITDA/mt for phosphate fertilizers (DAP and NPK) stood at INR7,398 (up 17% YoY).
- EBIT margin for the nutrient & other allied business contracted 130bp YoY to 11.4%, while EBIT margin for the crop protection business contracted ~80bp YoY to 13.6% (Due to the consolidation of NACL). However, standalone EBIT margins expanded 500bp YoY to 19.5%.
- Adjusted PAT stood at INR8.1b (est. in line), up 21% YoY.
- CRIN's 1HFY26 revenue/EBITDA/Adj. PAT grew 37%/30%/34% to INR167b/INR19.3b/INR13.1b. Total manufactured fertilizer volume (NPK + DAP) grew 4% YoY to ~2mmt, and total phosphate fertilizer manufacturing volumes (including SSP) grew 4% YoY to 2.38mmt.

### Highlights from the management commentary

- **Outlook:** Healthy performance is expected to continue in 2HFY26, driven by a favorable rabi season outlook, the announcement of NBS rates, above-normal reservoir levels, and the anticipated normalization of weather conditions following the unseasonal rainfall.

**Research Analyst: Sumant Kumar** (Sumant.Kumar@MotilalOswal.com) | **Meet Jain** (Meet.Jain@MotilalOswal.com)

**Research Analyst: Nirvik Saini** (Nirvik.Saini@MotilalOswal.com) | **Yash Darak** (Yash.Darak@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

- **Subsidy:** During the quarter, CRIN received INR33.4b/INR46.4b in subsidy claims for 2Q/1HFY26, compared to INR38.5b in 1QFY25. As of Sep'25, outstanding subsidies stood at ~INR32b compared to INR17.1b as of Sep'24.
- **Crop protection:** The export business, driven by strong momentum in Mancozeb, grew 6-7% during the quarter with a significant improvement in profitability, making it a key contributor to the overall performance of crop protection. The company continues to enhance its export portfolio through capacity expansion and the development of new molecules.

### Valuation and view

- We believe the company is well-positioned to sustain its growth momentum in FY26, supported by favorable market dynamics, increasing shift toward NPK fertilizers for balanced nutrition, and strong growth in crop protection led by synergy benefits of the NACL consolidation.
- CRIN's medium-term outlook remains strong, backed by: 1) expansion into new geographies, 2) development of new molecules across fertilizers and crop protection segments, 3) backward integration for the fertilizer business, 4) acquisition of NACL, and 5) the scale-up of BMCC.
- We have modeled the acquisition of NACL Industries completed during the quarter and raised our revenue estimates by 5%/7%/8% and earnings estimates by 4% for FY26/FY27/FY28, respectively. We value the company at ~28x FY27E EPS to arrive at a TP of **INR2,800. Reiterate BUY**

### Quarterly Performance


												(INR m)
Y/E March	FY25				FY26				FY25	FY26E	FY26	Var
Consolidated	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	%
<b>Net Sales</b>	<b>47,288</b>	<b>74,328</b>	<b>69,352</b>	<b>49,884</b>	<b>70,423</b>	<b>96,541</b>	<b>84,774</b>	<b>61,017</b>	<b>2,40,852</b>	<b>3,12,755</b>	<b>85,817</b>	<b>12</b>
YoY Change (%)	-16.9	6.4	26.9	27.5	48.9	29.9	22.2	22.3	9.2	29.9	15.5	
Total Expenditure	42,231	64,581	62,134	45,624	62,602	85,076	76,147	55,334	2,14,569	2,79,159	74,641	
<b>EBITDA</b>	<b>5,058</b>	<b>9,748</b>	<b>7,218</b>	<b>4,260</b>	<b>7,821</b>	<b>11,465</b>	<b>8,627</b>	<b>5,683</b>	<b>26,283</b>	<b>33,596</b>	<b>11,176</b>	<b>3</b>
Margins (%)	10.7	13.1	10.4	8.5	11.1	11.9	10.2	9.3	10.9	10.7	13.0	
Depreciation	653	690	708	854	1,206	1,018	1,215	1,220	2,904	4,658	1,210	
Interest	574	661	731	659	680	1,018	550	450	2,624	2,698	660	
Other Income	541	650	1,137	1,260	837	1,165	1,307	1,389	3,587	4,698	900	
<b>PBT before EO expense</b>	<b>4,372</b>	<b>9,047</b>	<b>6,916</b>	<b>4,007</b>	<b>6,773</b>	<b>10,595</b>	<b>8,169</b>	<b>5,402</b>	<b>24,342</b>	<b>30,938</b>	<b>10,206</b>	
Extra-Ord expense	0	0	0	-3,468	0	0	0	0	-3,468	0	0	
<b>PBT</b>	<b>4,372</b>	<b>9,047</b>	<b>6,916</b>	<b>7,475</b>	<b>6,773</b>	<b>10,595</b>	<b>8,169</b>	<b>5,402</b>	<b>27,810</b>	<b>30,938</b>	<b>10,206</b>	
Tax	1,125	2,328	1,752	1,524	1,757	2,660	2,056	1,368	6,728	7,841	2,569	
Rate (%)	25.7	25.7	25.3	20.4	25.9	25.1	25.2	25.3	24.2	25.3	25.2	
MI & P/L of Asso. Cos.	137	79	46	154	-34	-119	-36	152	417	-37	-50	
<b>Reported PAT</b>	<b>3,110</b>	<b>6,641</b>	<b>5,118</b>	<b>5,797</b>	<b>5,050</b>	<b>8,053</b>	<b>6,149</b>	<b>3,882</b>	<b>20,665</b>	<b>23,134</b>	<b>7,687</b>	
<b>Adj PAT</b>	<b>3,110</b>	<b>6,641</b>	<b>5,118</b>	<b>3,036</b>	<b>5,050</b>	<b>8,053</b>	<b>6,149</b>	<b>3,882</b>	<b>18,036</b>	<b>23,134</b>	<b>7,687</b>	<b>5</b>
YoY Change (%)	-37.1	-12.3	121.6	89.4	62.4	21.3	20.1	27.9	9.8	28.3	15.8	
Margins (%)	6.6	8.9	7.4	6.1	7.2	8.3	7.3	6.4	7.5	7.4	9.0	

## Key Performance Indicators

Y/E March	FY25				FY26		FY25	FY26E
Consolidated	1Q	2Q	3Q	4Q	1Q	2Q		
Volume Growth (%)	-3.4	24.6	14.6	23.6	28.2	12.7	14.9	12.6
Manufacturing (%)	3.3	6.3	7.6	22.8	11.8	-1.6	8.7	4.6
Trading (%)	-22.4	116.1	28.3	24.8	89.9	47.8	30.6	89.9
Mfg EBITDA/MT (INR)	4,261	5,435	4,609	4,177	5,118	6,340	4,150	4,799
<b>Cost Break-up</b>								
RM Cost (% of sales)	73.6	74.9	76.4	70.3	74.4	76.3	74.1	74.4
Staff Cost (% of sales)	3.9	2.5	3.0	4.2	3.2	2.7	3.3	3.3
Freight Cost (% of sales)	6.0	5.0	5.4	6.4	5.4	4.1	5.6	5.2
Other Cost (% of sales)	5.8	4.5	4.9	10.6	5.9	5.0	6.1	6.3
Gross Margins (%)	26.4	25.1	23.6	29.7	25.6	23.7	25.9	25.6
EBITDA Margins (%)	10.7	13.1	10.4	8.5	11.1	11.9	10.9	10.7
EBIT Margins (%)	9.3	12.2	9.4	6.8	9.4	10.8	9.7	9.3


## Key exhibits

**Exhibit 1: Revenue trend**




Source: Company, MOFSL

**Exhibit 2: EBITDA trend**




Source: Company, MOFSL

**Exhibit 3: Adjusted PAT trend**




Source: Company, MOFSL

**Exhibit 4: Trend in outstanding subsidy**



Source: Company, MOFSL

**Exhibit 5: Price trend in phosphoric acid**



Source: Company, Bloomberg, MOFSL

**Exhibit 6: Segmental revenue and EBIT trends**

INR m	1QFY25	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26
<b>Segment revenue</b>										
Nutrient and Other Allied	52,006	63,017	49,027	33,702	42,137	67,503	63,674	43,210	63,517	86,609
YoY growth (%)	2%	-33%	-36%	-31%	-19%	7%	30%	28%	51%	28%
Crop Protection	5,475	7,301	6,154	5,644	5,516	7,511	6,357	6,987	7,249	10,689
YoY growth (%)	-17%	3%	-6%	-8%	1%	3%	3%	24%	31%	42%
Less: Inter-segment	547	437	540	219	364	686	678	313	343	756
<b>Total</b>	<b>56,934</b>	<b>69,881</b>	<b>54,642</b>	<b>39,127</b>	<b>47,288</b>	<b>74,328</b>	<b>69,352</b>	<b>49,884</b>	<b>70,423</b>	<b>96,541</b>
<b>Segment EBIT</b>										
Nutrient and Other Allied	6,717	9,913	2,516	2,515	4,317	8,507	6,261	2,973	6,295	9,834
Margin (%)	12.9%	15.7%	5.1%	7.5%	10.2%	12.6%	9.8%	6.9%	9.9%	11.4%
Crop Protection	550	871	846	631	629	1,083	910	1,011	1,112	1,452
Margin (%)	10.0%	11.9%	13.7%	11.2%	11.4%	14.4%	14.3%	14.5%	15.3%	13.6%
Unallocated expenses	656	737	419	1,046	540	532	661	1,088	-791	838
<b>Total</b>	<b>6,611</b>	<b>10,048</b>	<b>2,943</b>	<b>2,100</b>	<b>4,405</b>	<b>9,058</b>	<b>6,510</b>	<b>2,897</b>	<b>8,197</b>	<b>10,448</b>

Source: Company, MOFSL

**Exhibit 7: Volume trend**

Quarterly volume trend ('000MT)	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26
<b>Manufactured</b>									
NPK	994	817	506	726	1,086	912	607	893	1,073
Growth (%)	-7%	-8%	-5%	2%	9%	12%	20%	23%	-1%
DAP	33	59	33	85	0	0	0	0	0
Growth (%)	-3%	111%	371%	93%	-100%	-100%	-100%	-100%	-100%
SSP	212	143	119	157	231	184	201	189	223
Growth (%)	-13%	-34%	-37%	-12%	9%	29%	69%	20%	-3%
<b>Total Manufacturing</b>	<b>1,239</b>	<b>1,019</b>	<b>658</b>	<b>968</b>	<b>1,317</b>	<b>1,096</b>	<b>808</b>	<b>1,082</b>	<b>1,296</b>
Growth (%)	-8%	-10%	-10%	3%	6%	8%	23%	12%	-2%
<b>Traded</b>									
MOP	37	22	12	7	29	20	13	6	14
Growth (%)	85%	1000%	1100%	-36%	-22%	-9%	8%	-14%	-52%
DAP Traded	132	62	51	27	181	227	97	193	236
Growth (%)	-4%	-54%	-41%	-72%	37%	266%	90%	615%	30%
NPK Traded	0	0	0	0	43	0	0	14	97
Urea	79	436	372	223	283	420	433	275	445
Growth (%)	-79%	9%	-31%	0%	258%	-4%	16%	23%	57%
<b>Total Trading</b>	<b>248</b>	<b>520</b>	<b>435</b>	<b>257</b>	<b>536</b>	<b>667</b>	<b>543</b>	<b>488</b>	<b>792</b>
Growth (%)	-53%	-3%	-31%	-22%	116%	28%	25%	90%	48%
<b>Total Trading + Mfg.</b>	<b>1,487</b>	<b>1,539</b>	<b>1,093</b>	<b>1,225</b>	<b>1,853</b>	<b>1,763</b>	<b>1,351</b>	<b>1,570</b>	<b>2,088</b>
Growth (%)	-21%	-8%	-20%	-3%	25%	15%	24%	28%	13%
<b>Total NPK (mfg. + trading)</b>	<b>994</b>	<b>817</b>	<b>506</b>	<b>726</b>	<b>1,129</b>	<b>912</b>	<b>607</b>	<b>907</b>	<b>1,170</b>
Growth (%)	-7%	-8%	-5%	2%	14%	12%	20%	25%	4%
<b>Total DAP (mfg. + trading)</b>	<b>165</b>	<b>121</b>	<b>84</b>	<b>112</b>	<b>181</b>	<b>227</b>	<b>97</b>	<b>193</b>	<b>236</b>
Growth (%)	-4%	-26%	-11%	-21%	10%	88%	15%	72%	30%
<b>Total phosphatic fertilizer</b>	<b>1,159</b>	<b>938</b>	<b>590</b>	<b>838</b>	<b>1,310</b>	<b>1,139</b>	<b>704</b>	<b>1,100</b>	<b>1,406</b>
Growth (%)	-7%	-11%	-6%	-2%	13%	21%	19%	31%	7%

Source: Company, MOFSL



## Highlights from the management commentary

### Industry scenario

- With favorable monsoons and a strong agrarian sentiment across key markets, the company has proactively expanded its sales and distribution efforts to ensure the timely availability of fertilizers to farmers.
- India received 8% above-normal rainfall vs the long-period average, with widespread rains except for in parts of eastern India.
- Excess and unseasonal rains that occurred in August and September affected the standing crops as well as impacted the application of crop inputs and specialty products.
- Reservoir levels remain healthy, above the last year's level and 16% above the normal storage.
- On the policy front, the government has been taking proactive steps on supporting agriculture and agri inputs.
- CRIN's fertilizer plants operated at full capacity. The company grew its sales volumes by 17% in 1H by expanding its presence in existing and new markets, thereby consolidating its position as market leader in phosphatic.
- Key raw materials, such as urea and rock phosphate, have seen price softness, while international DAP prices have also begun easing, likely cascading into other input costs.
- Phosphoric acid prices were renegotiated in 2Q, moving up marginally from INR1258 to INR1290.

### Outlook

- Management expects continued strong performance in 2HFY26, with the impact of unseasonal rainfall expected to subside and a healthy rabbi season on the back of the NBS rates announcement and above-normal reservoir levels.
- Management is targeting a minimum of INR5,500 EBITDA per metric ton in fertilizers while aiming for 100% utilization of new acid plants in FY27.

### Subsidy

- The subsidy business share in the revenue stands at 83% for both 1HFY26 and 2QFY26. It is broadly in line with last year's figure of ~84% and 83% in 1HFY25.
- Subsidiary business share in EBITDA stood at 71% for the quarter and 70% for the first half of the year, compared to ~73% in 1QFY25 and 72% in 1HFY25.
- The company has received INR33.4b towards subsidy claims in the quarter, bringing the total for the half year to INR46.3b.

### NPK

- The share of NPK in the overall phosphatic consumption rose to 64%, compared to the earlier equal split between DAP and NPK, indicating a favorable shift toward balanced nutrient application.
- The adoption of NP and NPK fertilizers in northern markets has been gradually increasing, which bodes well for CRIN, given its strong presence in NP and NPK manufacturing.
- The NBS policy allows pricing flexibility for NPK fertilizers, enabling the company to balance farmer needs and input costs. Management stated that price revisions will be made as needed, in line with its practice of timely price corrections.

### **Crop protection business**

- The Crop Protection business delivered a resilient performance, driven by strong growth in technical sales in global markets and healthy traction in domestic formulations segment. The business expanded its product portfolio, launching several new products during 1HFY26.
- During the quarter, CRIN successfully completed the acquisition of NACL Industries, followed by the mandatory open offer, emerging as one of the leading crop protection players in the country.
- Overall inventory hangover has normalized, enabling volume improvement in the off-take of key molecules.
- Excess unseasonal rains in August and September affected spraying activities during the Kharif season, but the improved outlook for the Rabi season is expected to offset the volume impact in the coming months.
- The export business, driven primarily by Mancozeb, recorded strong growth in both volume and profitability, emerging as a key contributor to quarterly and half-year performance. Mancozeb exports are expected to remain a major focus area for the full year.
- The export business grew by 6-7% during the quarter, with profitability showing a strong improvement
- The company is developing several new molecules and has expanded capacities to support this growth. A new molecule, Pyraclostrobin, is also under development.
- September rains impacted formulation sales volumes; however, the business continued to perform well with ~11% growth for the quarter and ~20% growth YTD. Overall, the company expects ~25% annual growth in the formulation segment over last year.

### **Nutrient and Allied Business**

- The brownfield expansion projects for sulphuric acid and phosphoric acid plants at Kakinada are progressing as per schedule and are expected to be commissioned in 4QFY26.
- The company has also initiated activities to enhance its NPK production capacity.
- During the quarter, CRIN signed strategic supply contracts with leading global partners to secure key raw materials and finished products.
- The Specialty Nutrients business delivered a strong quarter, with notable improvement in sales and margins.
- The company is focused on increasing sulphur volumes following last year's capacity expansion, and is diversifying the portfolio to include sulphur-plus-micronutrient products.
- An investment in a Mono Ammonium Phosphate (MFP) plant at Vizag is announced to reduce dependence on China for key raw materials used in water-soluble fertilizers. These strategic investments in granulation and MFP plants will help broaden the product portfolio, enhance resource efficiency, and ensure the availability of key nutrients at affordable prices, supporting long-term growth.

### **Retail**

- The Retail business continued its steady expansion, adding around 100 new stores during Q2 and crossing the landmark of 1,000 stores.
- The company has expanded its retail presence into new states, including Maharashtra and Tamil Nadu, and is on track to reach 1,200 stores.



- All retail segments performed well, with a notable increase in fertilizer sales volumes through retail outlets.

### Others

- The company has also announced plans to set up a water-soluble MAP fertilizer facility.
- Spraying services through drones have gained momentum. In fact, the company is confident in its ability to cover almost 80,000 acres in the current year.
- The domestic B2C segment delivered an exceptional quarter despite a challenging business environment, achieving strong numbers early in the Kharif season. While unseasonal rains impacted offtake.
- The company continued to expand its presence, entering around 40 new markets and launching several new in-licensed products during the year. Revenue rose 11% in new markets.
- An increasing number of farmers are recognizing the benefits of balanced crop nutrition, which represents a positive step forward for the agricultural sector as a whole.
- The phosphoric acid plant is expected to achieve mechanical completion by December, with trial runs in January and commercial production commencing by the second or third week of January.
- The company plans to debottleneck capacities in both fertilizer and PTC segments and is pursuing new product registrations along with capacity expansion for active ingredients.
- It also aims to develop downstream projects for Mancozeb and other molecules to enhance material security and capture greater value across the CPC value chain, similar to its approach in fertilizers. A strong pipeline of projects is currently underway to support these initiatives.
- BMCC has turned profitable at the operational level, supported by ongoing scaling efforts. While the impact may not be significant at the consolidated level due to accounting adjustments related to the initial acquisition, the core business performance remains strong and profitable.

### Valuation and view

- We believe the company is well-positioned to sustain its growth momentum in FY26, supported by favorable market dynamics, increasing shift toward NPK fertilizers for balanced nutrition, and strong growth in crop protection led by synergy benefits of the NACL consolidation.
- CRIN's medium-term outlook remains strong, backed by: 1) expansion into new geographies, 2) development of new molecules across the fertilizers and crop protection segments, 3) backward integration for the fertilizer business, 4) acquisition of NACL, and 5) the scale up of BMCC.
- We have modeled the acquisition of NACL Industries completed during the quarter and raised our revenue estimates by 5%/7%/8% and earnings estimates by 4% for FY26/FY27/FY28, respectively. We value the company at ~28x FY27E EPS to arrive at a TP of **INR2,800. Reiterate BUY**

### Exhibit 8: Revisions to our estimates

Earnings Change (INR m)	Old			New			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	2,96,799	3,24,556	3,47,862	3,12,755	3,48,669	3,74,260	5%	7%	8%
EBITDA	32,479	39,760	43,839	33,596	41,592	45,826	3%	5%	5%
Adj. PAT	22,253	28,631	32,417	23,134	29,661	33,568	4%	4%	4%

Source: MOFSL



## Financials and valuations

### Consolidated - Income Statement

(InRm)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Total Income from Operations</b>	<b>1,41,820</b>	<b>1,91,109</b>	<b>2,96,279</b>	<b>2,20,584</b>	<b>2,40,852</b>	<b>3,12,755</b>	<b>3,48,669</b>	<b>3,74,260</b>
Change (%)	8.0	34.8	55.0	(25.5)	9.2	29.9	11.5	7.3
<b>Total Expenditure</b>	<b>1,21,977</b>	<b>1,69,610</b>	<b>2,67,017</b>	<b>1,96,596</b>	<b>2,14,569</b>	<b>2,79,159</b>	<b>3,07,077</b>	<b>3,28,434</b>
<b>EBITDA</b>	<b>19,843</b>	<b>21,499</b>	<b>29,262</b>	<b>23,988</b>	<b>26,283</b>	<b>33,596</b>	<b>41,592</b>	<b>45,826</b>
Margin (%)	14.0	11.2	9.9	10.9	10.9	10.7	11.9	12.2
Depreciation	1,731	1,727	1,820	2,286	2,904	4,658	5,460	5,496
<b>EBIT</b>	<b>18,112</b>	<b>19,772</b>	<b>27,442</b>	<b>21,702</b>	<b>23,379</b>	<b>28,938</b>	<b>36,132</b>	<b>40,330</b>
Int. and Finance Charges	1,057	755	1,900	1,866	2,624	2,698	1,600	1,500
Other Income	751	1,443	1,711	2,314	3,587	4,698	5,638	6,766
<b>PBT bef. EO Exp.</b>	<b>17,806</b>	<b>20,460</b>	<b>27,253</b>	<b>22,150</b>	<b>24,342</b>	<b>30,938</b>	<b>40,170</b>	<b>45,596</b>
EO Expense/(Income)	0	0	0	0	3,468	0	0	0
<b>PBT after EO Exp.</b>	<b>17,806</b>	<b>20,460</b>	<b>27,253</b>	<b>22,150</b>	<b>27,810</b>	<b>30,938</b>	<b>40,170</b>	<b>45,596</b>
Total Tax	4,568	5,213	6,879	5,478	6,728	7,841	10,111	11,477
Tax Rate (%)	25.7	25.5	25.2	24.7	24.2	25.3	25.2	25.2
Less: MI/Sh of profit/loss of JV & Ass.	-54	-37	245	250	417	-37	398	551
<b>Reported PAT</b>	<b>13,292</b>	<b>15,285</b>	<b>20,129</b>	<b>16,422</b>	<b>20,665</b>	<b>23,134</b>	<b>29,661</b>	<b>33,568</b>
<b>Adjusted PAT</b>	<b>13,292</b>	<b>15,285</b>	<b>20,129</b>	<b>16,422</b>	<b>18,036</b>	<b>23,134</b>	<b>29,661</b>	<b>33,568</b>
Change (%)	24.8	15.0	31.7	-18.4	9.8	28.3	28.2	13.2
Margin (%)	9.4	8.0	6.8	7.4	7.5	7.4	8.5	9.0

### Consolidated - Balance Sheet

(InRm)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	293	294	294	294	294	294	294	294
Total Reserves	51,213	63,289	78,784	93,905	1,10,584	1,29,596	1,55,136	1,84,583
<b>Net Worth</b>	<b>51,506</b>	<b>63,583</b>	<b>79,078</b>	<b>94,199</b>	<b>1,10,878</b>	<b>1,29,891</b>	<b>1,55,430</b>	<b>1,84,877</b>
Deferred Liabilities	576	660	591	827	837	837	837	837
Total Loans	16	0	46	518	2,322	1,322	822	322
<b>Capital Employed</b>	<b>52,098</b>	<b>64,243</b>	<b>79,715</b>	<b>95,814</b>	<b>1,15,386</b>	<b>1,33,399</b>	<b>1,58,438</b>	<b>1,87,385</b>
Gross Block	36,849	39,337	42,245	46,769	51,506	70,080	75,531	79,281
Less: Accum. Deprn.	16,698	18,424	20,244	22,529	25,433	30,092	35,552	41,048
<b>Net Fixed Assets</b>	<b>20,151</b>	<b>20,913</b>	<b>22,001</b>	<b>24,240</b>	<b>26,073</b>	<b>39,988</b>	<b>39,979</b>	<b>38,233</b>
Goodwill on Consolidation	3	3	3	2,849	2,849	6,702	6,702	6,702
Capital WIP	898	1,412	3,993	2,355	3,525	2,951	2,500	3,750
Current Investments	0	0	0	0	0	0	0	0
<b>Total Investments</b>	<b>2,138</b>	<b>2,435</b>	<b>2,867</b>	<b>8,538</b>	<b>10,308</b>	<b>10,308</b>	<b>10,308</b>	<b>10,308</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>65,765</b>	<b>88,085</b>	<b>1,13,484</b>	<b>1,20,534</b>	<b>1,46,418</b>	<b>1,56,482</b>	<b>1,91,228</b>	<b>2,27,064</b>
Inventory	26,009	36,632	44,165	46,125	47,699	55,696	62,092	66,649
Account Receivables	5,544	2,649	5,893	13,935	12,291	14,567	15,284	16,406
Govt Subsidies Receivable	5,897	2,941	23,779	13,772	16,536	21,422	23,881	25,634
Cash and Bank Balance	7,221	17,533	14,178	28,586	35,383	26,239	55,582	81,461
Loans and Advances	21,094	28,330	25,470	18,116	34,509	38,559	34,389	36,913
<b>Curr. Liability &amp; Prov.</b>	<b>36,857</b>	<b>48,605</b>	<b>62,633</b>	<b>62,702</b>	<b>73,890</b>	<b>83,135</b>	<b>92,382</b>	<b>98,775</b>
Account Payables	29,222	39,135	53,138	53,606	60,300	70,120	76,992	82,287
Other Current Liabilities	7,281	9,132	9,057	8,606	12,995	11,996	14,329	15,381
Provisions	354	337	439	489	595	1,019	1,061	1,107
<b>Net Current Assets</b>	<b>28,908</b>	<b>39,481</b>	<b>50,851</b>	<b>57,832</b>	<b>72,529</b>	<b>73,347</b>	<b>98,846</b>	<b>1,28,289</b>
<b>Appl. of Funds</b>	<b>52,098</b>	<b>64,243</b>	<b>79,715</b>	<b>95,814</b>	<b>1,15,386</b>	<b>1,33,399</b>	<b>1,58,438</b>	<b>1,87,385</b>

## Financials and valuations

### Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
<b>Basic (INR)</b>								
<b>EPS</b>	<b>45.3</b>	<b>52.1</b>	<b>68.5</b>	<b>55.8</b>	<b>61.3</b>	<b>78.6</b>	<b>100.8</b>	<b>114.0</b>
Cash EPS	51.2	58.0	74.7	63.5	71.1	94.4	119.3	132.7
BV/Share	175.5	216.6	269.0	320.0	376.6	441.2	528.0	628.0
DPS	12.0	12.0	12.0	12.0	14.0	14.0	14.0	14.0
Payout (%)	26.5	23.0	17.5	21.5	19.9	17.8	13.9	12.3
<b>Valuation (x)</b>								
P/E	46.9	40.8	31.0	38.1	34.7	27.0	21.1	18.6
Cash P/E	41.5	36.7	28.5	33.4	29.9	22.5	17.8	16.0
P/BV	12.1	9.8	7.9	6.6	5.6	4.8	4.0	3.4
EV/Sales	4.3	3.2	2.1	2.7	2.5	1.9	1.6	1.5
EV/EBITDA	31.1	28.2	20.9	24.9	22.6	17.9	13.8	11.9
Dividend Yield (%)	0.6	0.6	0.6	0.6	0.7	0.7	0.7	0.7
FCF per share	121.3	60.6	1.4	29.0	69.0	-20.6	103.0	87.6
<b>Return Ratios (%)</b>								
RoE	28.1	26.6	28.2	19.0	17.6	19.2	20.8	19.7
RoCE	25.3	27.5	30.5	20.8	19.7	20.5	21.7	20.6
RoIC	27.4	34.8	40.4	28.4	28.9	27.0	29.4	33.2
<b>Working Capital Ratios</b>								
Fixed Asset Turnover (x)	4	5	7	5	5	4	5	5
Asset Turnover (x)	2.7	3.0	3.7	2.3	2.1	2.3	2.2	2.0
Inventory (Days)	67	70	54	76	72	65	65	65
Debtor (Days)	14	5	7	23	19	17	16	16
Govt Subs Receivable (days)	15	6	29	23	25	25	25	25
Creditor (Days)	110	100	83	119	123	110	110	110
Others (Days)								
Working Capital Turnover (Days)	56	42	45	48	56	55	45	46
<b>Leverage Ratio (x)</b>								
Current Ratio	1.8	1.8	1.8	1.9	2.0	1.9	2.1	2.3
Interest Cover Ratio	17	26	14	12	9	11	23	27
Debt/Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

### Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
NP/(Loss) Before Tax and EO Items	17,806	20,460	27,253	22,150	27,276	30,938	40,170	45,596
Depreciation	1,731	1,727	1,820	2,286	2,904	4,658	5,460	5,496
Interest & Finance Charges	1,057	755	189	-448	258	-2,001	-4,038	-5,266
Direct Taxes Paid	-4,568	-4,834	-7,038	-5,478	-7,187	-7,841	-10,111	-11,477
(Inc)/Dec in WC	25,476	3,716	-16,520	7,427	4,520	-9,963	3,843	-3,563
<b>CF from Operations</b>	<b>41,502</b>	<b>21,824</b>	<b>5,703</b>	<b>25,936</b>	<b>27,771</b>	<b>15,792</b>	<b>35,325</b>	<b>30,786</b>
Others	0	-1,044	207	-11,659	-3,133	0	0	0
<b>CF from Operating incl EO</b>	<b>41,502</b>	<b>20,781</b>	<b>5,910</b>	<b>14,277</b>	<b>24,638</b>	<b>15,792</b>	<b>35,325</b>	<b>30,786</b>
(inc)/dec in FA	-5,926	-3,002	-5,489	-5,732	-4,335	-21,853	-5,000	-5,000
<b>Free Cash Flow</b>	<b>35,576</b>	<b>17,779</b>	<b>421</b>	<b>8,545</b>	<b>20,303</b>	<b>-6,061</b>	<b>30,325</b>	<b>25,786</b>
(Pur)/Sale of Investments	-25	-297	-432	-5,671	-45,620	0	0	0
Others	-6,622	-12,921	12,312	-1,940	23,578	4,698	5,638	6,766
<b>CF from Investments</b>	<b>-12,572</b>	<b>-16,220</b>	<b>6,390</b>	<b>-13,343</b>	<b>-26,377</b>	<b>-17,155</b>	<b>638</b>	<b>1,766</b>
Issue of Shares	0	0	1	0	168	0	0	0
Inc/(Dec) in Debt	-16,235	-16	46	472	-516	-1,000	-500	-500
Interest Paid	-1,057	-755	-1,900	-1,866	-2,150	-2,698	-1,600	-1,500
Dividend Paid	-3,521	-3,522	-3,528	-3,533	-3,528	-4,122	-4,122	-4,122
Others	-1,679	10,044	-10,273	18,400	14,563	37	-398	-551
<b>CF from Fin. Activity</b>	<b>-22,491</b>	<b>5,751</b>	<b>-15,655</b>	<b>13,474</b>	<b>8,537</b>	<b>-7,783</b>	<b>-6,620</b>	<b>-6,673</b>
<b>Inc/Dec of Cash</b>	<b>6,438</b>	<b>10,312</b>	<b>-3,355</b>	<b>14,408</b>	<b>6,798</b>	<b>-9,145</b>	<b>29,343</b>	<b>25,879</b>
Add: Beginning Balance	783	7,221	17,533	14,178	28,586	35,384	26,239	55,582

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://qalaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.raiani@motilaloswal.com](mailto:nainesh.raiani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.